Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD)
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to see if a drug called aldesleukin, can preserve insulin
production in children and young adults recently diagnosed with type 1 diabetes.
One group will receive aldesleukin and the other a placebo.
Phase:
Phase 2
Details
Lead Sponsor:
University of Oxford
Collaborators:
Centre for Statistics in Medicine, Oxford JDRF Juvenile Diabetes Research Foundation Oxford Clinical Trials Research Unit (OCTRU) Wellcome